
Mirum Pharmaceuticals, Inc.
NASDAQ•MIRM
CEO: Mr. Christopher Peetz
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2019-07-18
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Contact Information
Market Cap
$4.42B
P/E (TTM)
-125.5
40.4
Dividend Yield
--
52W High
$90.07
52W Low
$36.88
52W Range
Rank57Top 83.3%
2.4
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025
Financial Dashboard
Q3 2025 Data
Revenue
$133.01M+47.17%
4-Quarter Trend
EPS
$0.06-119.13%
4-Quarter Trend
FCF
$39.49M-737.31%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Surges Significantly Nine-month revenue reached $372.4M, marking a $135.4M increase driven by Livmarli and Bile Acid Medicines sales.
Operating Loss Narrows Nine-month net loss improved to $(17.6M) from $(64.2M) last year, reflecting operational leverage gains.
Cash Position Strengthened Unrestricted cash, equivalents, and investments grew to $378.0M as of September 30, 2025, up from $292.8M previously.
Increased R&D Investment Nine-month R&D expenses rose $38.5M to $135.1M, supporting pipeline advancement for volixibat and MRM-3379.
Risk Factors
Competition Threatens Sales Significant competition exists from IBATi developers like GSK and Ipsen, potentially limiting market acceptance and profitability.
Financing Needs Remain High Substantial additional financing is required for development plans; failure to secure capital delays programs or limits strategy.
Regulatory/IP Protection Uncertainty Reliance on method-of-use patents for Livmarli; IP protection is uncertain, risking generic or competitor product entry.
Revenue Fluctuation Risk Product revenue experiences quarter-to-quarter variation due to large, periodic, variable consideration orders from Takeda.
Outlook
Livmarli Expansion Progressing Expect completion of Livmarli EXPAND study enrollment in 2026, with topline data anticipated in the first half of 2027.
Volixibat Trials Advancing VISTAS Phase 2b trial in PSC completed enrollment in Q3 2025; topline data expected in Q2 2026.
Continued Operating Losses Anticipate continued net losses for the foreseeable future while commercializing approved medicines and funding clinical trials.
Convertible Notes Conversion Notes are convertible at holder option in Q4 2025, potentially causing stockholder dilution if settled via common stock issuance.
Peer Comparison
Revenue (TTM)
ACAD$1.05B
ADMA$488.56M
MIRM$471.79M
Gross Margin (Latest Quarter)
SLNO98.3%
ACAD92.2%
QURE89.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ACAD | $4.50B | 17.2 | 32.3% | 4.1% |
| MIRM | $4.42B | -125.5 | -16.5% | 40.6% |
| ADMA | $4.27B | 20.4 | 54.0% | 14.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
10.2%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 25, 2026
EPS:-$0.08
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 4, 2025|Revenue: $133.01M+47.2%|EPS: $0.06-119.1%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $127.79M+64.1%|EPS: $-0.12-76.9%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 7, 2025|Revenue: $111.59M+61.2%|EPS: $-0.30-44.4%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 26, 2025|Revenue: $336.89M+80.8%|EPS: $-1.85+53.8%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 12, 2024|Revenue: $90.38M+89.4%|EPS: $-0.30-47.4%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 7, 2024|Revenue: $77.88M+107.7%|EPS: $-0.52-73.2%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 8, 2024|Revenue: $69.22M+119.1%|EPS: $-0.54-32.5%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 15, 2024|Revenue: $186.37M+141.8%|EPS: $-4.00+0.2%Miss